|

Non-invasive Brain Tumor Molecular Diagnostics and Monitoring

RECRUITINGSponsored by The Institute of Molecular and Translational Medicine, Czech Republic
Actively Recruiting
SponsorThe Institute of Molecular and Translational Medicine, Czech Republic
Started2020-01-01
Est. completion2028-12-31
Eligibility
Age18 Years – 99 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06501521

Summary

This prospective multicenter study aims to enroll GBM patients who will undergo repeated assessments (preoperatively and 3 months post-surgery) to detect circulating tumor cells and analyze the transcriptomic profiles of EVs in their blood. The prognostic and monitoring significance of these biomarkers to disease course (assessing treatment efficacy, resistance incidence, tumor progression) will be evaluated. Concurrently, proteomic profiles typical of GBM will be analyzed in blood and ocular secretion samples from GBM patients, patients with low-grade gliomas, and patients without brain tumors to identify and validate novel protein biomarkers suitable for disease monitoring. Additionally, this study proposes an innovative approach to monitor GBM patients by investigating the presence of GBM-specific nucleic acid fragments in urine.

Eligibility

Age: 18 Years – 99 YearsHealthy volunteers accepted
Inclusion Criteria: Adult patients with brain tumors -

Exclusion Criteria: No other cancer; no inflammatory disease

\-

Conditions2

Brain TumorCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.